Impact Factor
3.77
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.52
1,657 total citations
h5-index
46
h5 depth signal
Cited share
74.8%
360 of 481
Total citations
1,657
Citation footprint
Metric signal
3.58
External metric anchor
Self-citation
7.4%
122 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,051
Italy
497
United Kingdom
418
Canada
393
Germany
321
Citing Fields of Research
Neuromuscular Disorders
2,488
Nervous System Disorders
325
Neurodegenerative Disorders
303
Neurosciences
171
Immunology
86
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
6,963
Articles tracked across the journal lifetime
Indexed publication set
481
360 cited publications
Last 12 months
240
20.0 publications/month
Open access share
38.8%
93 OA publications in the last year
Leading citing country
United States
1,051 citing publications
Leading citing field
Neuromuscular Disorders
2,488 citing publications
Latest tracked publication
18 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Apr. 1995-
v1n1,Apr. 1995-
Active Coverage
Research Focus & Classification
Indexed Subjects
Neuromuscular Disorders
Broad Categories
Neurology
Neuromuscular Disorders
MeSH Descriptors
Central Nervous System Diseases
Demyelinating Diseases
Inflammation
Multiple Sclerosis
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/13524585261496111
Open DOI
Rituximab versus ocrelizumab: When inference exceeds the evidence
02
DOI 10.1177/13524585261496131
Open DOI
Author response—Rituximab versus ocrelizumab: When inference exceeds the evidence
03
DOI 10.1177/13524585261495351
Open DOI
Lymphocytosis as a biomarker for natalizumab treatment response in multiple sclerosis: The link with anti-drug antibodies
Background: Natalizumab is a high-efficacy therapy drug for multiple sclerosis that inhibits lymphocyte migration into the central nervous system, increasing lymphocyte counts in the peripheral blood. Anti-drug antibody responses may lim...
04
DOI 10.1177/13524585261494379
Open DOI
Increased autoimmune disease burden before multiple sclerosis and neuromyelitis optica spectrum disorder diagnosis: A nationwide Korean cohort study
Background: A prodromal phase is increasingly recognized in multiple sclerosis and neuromyelitis optica spectrum disorder, but the temporal patterns of autoimmune diseases remain poorly characterized. Objectives: To evaluate the risk and...
05
DOI 10.1177/13524585261491122
Open DOI
Who declines neurocognitive testing? A cross-sectional study in people with multiple sclerosis
In 334 people with multiple sclerosis, a backward stepwise regression analysis was conducted to identify clinical characteristics that predict who declines neurocognitive testing ( p < 0.05), from demographics, disease-related variables,...
06
DOI 10.1177/13524585261492525
Open DOI
Validation of generative artificial intelligence techniques for synthetic data generation in multiple sclerosis research: A comparison with real-world evidence from the Italian multiple sclerosis registry
Background: The use of generative artificial intelligence to create synthetic data is an emerging strategy to enhance real-world evidence. Objective: To assess the validity of artificial intelligence-generated synthetic data in replicati...
07
DOI 10.1177/13524585261490350
Open DOI
Survivor bias and disease progression in observational cohorts in multiple sclerosis
Background: Long-term studies on multiple sclerosis progression often face dropout, possibly among those with more aggressive disease, biasing the cohort. Objectives: We assessed potential survivorship bias in a long-term observational m...
08
DOI 10.1177/13524585261492141
Open DOI
How well do junior neurology residents recognize multiple sclerosis? Analysis of the “Close the Loop” resident clinical acumen project
Purpose: To evaluate diagnostic accuracy and patterns of errors among junior neurology residents evaluating acute presentations of multiple sclerosis and other demyelinating diseases. Methods: We retrospectively reviewed a morning-report...
09
DOI 10.1177/13524585261492505
Open DOI
Multiple sclerosis and housing insecurity or forcible displacement: A scoping review
There is an increasing number of people experiencing housing insecurity and forcible displacement globally. We perform a scoping review, searching PubMed (1 January 1990–30 June 2026) for the key terms “housing insecurity,” “inadequate h...
10
DOI 10.1177/13524585261489061
Open DOI
Autologous haematopoietic stem cell transplantation affects paramagnetic rim lesions in multiple sclerosis
Background: Available literature shows a marginal or no effect of disease-modifying therapies on paramagnetic rim lesions (PRLs), a promising magnetic resonance imaging marker of chronic inflammation in multiple sclerosis. Objective: To ...
Bibliographical & Catalog Notes
Issues for Jan. 2011- have title: Multiple sclerosis journal.
Title from cover.
Also issued online.
Vol. 1, no. 1 (APR 1995)19960129 Notice published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper